| |
| |
|
| Insider
Information: |
Lowinger Timothy B |
| Relationship: |
SVP, Chief Sci.&Tech. ... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
199,329 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$418,591 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
199,329 |
|
|
| Total
Value |
$418,591 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -175.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Mersana Therapeutics, Inc. |
MRSN |
SVP, Chief Sci.&Tech. ... |
2024-01-16 |
199,329 |
2018-02-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
53 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRSN |
Mersana Therapeutics, Inc... |
SVP, Chief Sci.&Tech. Officer |
• – – |
2024-01-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,792 |
194,530 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
SVP, Chief Sci.&Tech. Officer |
• – – |
2024-01-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,208 |
209,738 |
0 |
- |
|
| MRSN |
Mersana Therapeutics, Inc... |
SVP, Chief Sci.&Tech. Officer |
• – – |
2024-01-16 |
4 |
AS |
$2.71 |
$28,208 |
D/D |
(10,409) |
199,329 |
0 |
% |
|
53 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
